Callahan Advisors LLC reduced its stake in shares of Natus Medical Incorporated (NASDAQ:BABY) by 31.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,625 shares of the medical equipment provider’s stock after selling 2,565 shares during the period. Callahan Advisors LLC’s holdings in Natus Medical were worth $211,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. grew its holdings in Natus Medical by 2,085.6% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock worth $102,000 after acquiring an additional 2,607 shares in the last quarter. Riverhead Capital Management LLC grew its holdings in Natus Medical by 90.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock worth $107,000 after acquiring an additional 1,364 shares in the last quarter. Sei Investments Co. grew its holdings in Natus Medical by 29.7% during the 2nd quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock worth $119,000 after acquiring an additional 728 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Natus Medical by 94.0% during the 1st quarter. Victory Capital Management Inc. now owns 3,184 shares of the medical equipment provider’s stock worth $125,000 after acquiring an additional 1,543 shares in the last quarter. Finally, Flinton Capital Management LLC grew its holdings in Natus Medical by 82.0% during the 2nd quarter. Flinton Capital Management LLC now owns 3,774 shares of the medical equipment provider’s stock worth $141,000 after acquiring an additional 1,700 shares in the last quarter. 94.44% of the stock is owned by institutional investors.
In other Natus Medical news, Director William M. Moore sold 3,000 shares of the stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $34.10, for a total transaction of $102,300.00. Following the sale, the director now owns 30,410 shares of the company’s stock, valued at approximately $1,036,981. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Robert A. Gunst sold 4,400 shares of the stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $35.17, for a total transaction of $154,748.00. Following the sale, the director now directly owns 50,850 shares in the company, valued at approximately $1,788,394.50. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.
BABY has been the subject of several recent analyst reports. Zacks Investment Research lowered shares of Natus Medical from a “hold” rating to a “sell” rating in a report on Friday, July 28th. BidaskClub lowered shares of Natus Medical from a “sell” rating to a “strong sell” rating in a report on Thursday, August 24th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. Natus Medical currently has a consensus rating of “Hold” and an average target price of $46.50.
Natus Medical Incorporated (BABY) traded down 0.12% on Monday, hitting $41.50. 97,491 shares of the stock traded hands. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of 71.92 and a beta of 0.95. Natus Medical Incorporated has a 12-month low of $31.65 and a 12-month high of $43.85. The stock has a 50-day moving average of $37.96 and a 200-day moving average of $36.19.
Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.02. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The firm had revenue of $122.60 million for the quarter, compared to analyst estimates of $122.41 million. During the same quarter in the previous year, the firm posted $0.39 EPS. The business’s revenue for the quarter was up 34.9% on a year-over-year basis. Analysts forecast that Natus Medical Incorporated will post $1.72 earnings per share for the current year.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
What are top analysts saying about Natus Medical Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Natus Medical Incorporated and related companies.